Interaction of aminoadamantane derivatives with the influenza A virus M2 channel-Docking using a pore blocking model

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 14, 2010, Pages 4182-4187

  Eleftheratos, Stelios ^a   Spearpoint, Philip ^c   Ortore, Gabriella ^b   Kolocouris, Antonios ^a   Martinelli, Adriano ^b   Martin, Stephen ^c   Hay, Alan ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF PISA   (Italy)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Amantadine; Aminoadamatanes; Binding constants; Docking calculations; Influenza A; M2TM blockers; Pore blocking model; Rimantadine; Trp fluorescence

Indexed keywords

ADAMANTANE DERIVATIVE; ALANINE; AMINO ACID; CARBONYL DERIVATIVE; HYDROGEN; HYDROXYL GROUP; LIGAND; M2 TRANSMEMBRANE PROTEIN; SERINE; UNCLASSIFIED DRUG; VALINE; VIRUS PROTEIN;

ARTICLE; BINDING AFFINITY; CALCULATION; CHEMICAL INTERACTION; CRYSTAL STRUCTURE; GAS; HYDROGEN BOND; INFLUENZA VIRUS A; MODEL; MOLECULAR DOCKING; NONHUMAN; PREDICTION; QUALITATIVE ANALYSIS; SIMULATION;

ADAMANTANE; AMINO ACID SEQUENCE; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; VIRAL MATRIX PROTEINS;

INFLUENZA A VIRUS;

EID: 77954088453     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.05.049     Document Type: Article

References (47)

1. Taubenberger J.K., Reid A.H., Lourens R.M., Wang R., Jin G., and Fanning T.G. Nature 437 (2005) 889
2. Wang T.T., and Palese P. Cell 137 (2009) 983
3. Maines T.R., Jayaraman A., Belser J.A., Wadford D.A., Pappas C., Zeng H., Gustin K.M., Pearce M.B., Viswanathan K., Shriver Z.H., Raman R., Cox N.J., Sasisekharan R., Katz J.M., and Tumpey T.M. Science 325 (2009) 484
4. Ilyushina N.A., Bovin N.V., Webster R.G., and Govorkova E.A. Antiviral Res. 70 (2006) 121
5. Jonges M., Lubben van der I.M., Dijkstra F., Verhoef L., Koopmans M., and Meijer A. Antiviral Res. 83 (2009) 290
6. Hay A.J., Wolstenholme A.J., Skehel J.J., and Smith M.H. EMBO J. 4 (1985) 3021
7. Hay A.J. Semin. Virol. 3 (1992) 21
8. Pinto L.H., Holsinger L.J., and Lamb R.A. Cell 69 (1992) 517
9. Grambas S., and Hay A.J. Virology 190 (1992) 11
10. Stouffer A.L., Acharya R., Salom D., Levine A.S., Di Costanzo L., Soto C.S., Tereshko V., Nanda V., Stayrook S., and DeGrado W. Nature 451 (2008) 596
11. Cady S.D., Schmidt-Rohr K., Wang J., Soto C.S., Degrado W.F., and Hong M. Nature 463 (2010) 689
12. Pinto L., Dieckmann G.R., Gandhi C.S., Papworth C.G., Braman J., Shaughnessy M.A., Lear J.D., Lamb R.A., and DeGrado W.F. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 11301
13. Hu J., Asbury T., Achuthan S., Li C., Bertram R., Quine J.R., Fu R., and Cross T.A. Biophys. J. 92 (2007) 4335
14. Tang Y., Zaitseva F., Lamb R.A., and Pinto L.H. J. Biol. Chem. 277 (2002) 39880
15. Pinto L.H., and Lamb R.A. J. Biol. Chem. 281 (2006) 8997
16. Duff K.C., Gilchrist P.J., Saxena A.M., and Bradshaw J.P. Virology 202 (1994) 2877
17. Sansom M.S., and Kerr I.D. Protein Eng. 6 (1993) 65
18. Khurana E., Dal Peraro M., DeVane R., Vemparala S., and DeGrado W.F. Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 1069
19. Intharathep P., Laohpongspaisan C., Rungrotmongkol T., Loisruangsin A., Malaisree M., Decha P., Aruksakunwong O., Chuenpennit K., Kaiyawet N., Sompornpisut P., Pianwanit S., and Hannongbua S. J. Mol. Graph. Modell. 27 (2008) 342
20. Laohpongspaisan C., Rungrotmongkol T., Intharathep P., Malaisree M., Decha P., Aruksakunwong O., Sompornpisut P., and Hannongbua S. J. Chem. Inf. Model. 49 (2009) 847
21. Wang C., Takeuchi K., Pinto L.H., and Lamb R.A. J. Virol. 67 (1993) 5585
22. Cady S.D., Mishanina T.V., and Hong M. J. Mol. Biol. 385 (2009) 1127
23. Laughlin, C. A.; Tseng, C. K. Antivirals Agents, RNA Viruses other than HIV. In Burger's Medicinal Chemistry, 5th ed., Wolff, M. E., Ed.; John Wiley & Sons: New York, 1997; Vol. 5, pp 571-595.
24. For some representative publications see: Kolocouris, A. Ph.D Thesis, National Documentation Center, Vas. Constantinou 48, Athens, Greece, 1995.
25. Kolocouris N., Foscolos G.B., Kolocouris A., Marakos P., Pouli N., Fytas G., Ikeda S., and De Clercq E. J. Med. Chem. 37 (1994) 2896
26. Kolocouris N., Kolocouris A., Foscolos G., Fytas G., Neyts J., Padalko E., Balzarini J., Snoeck R., Andrei G., and De Clercq E. J. Med. Chem. 39 (1996) 3307
27. Stamatiou G., Kolocouris A., Kolocouris N., Fytas G., Foscolos G.B., Neyts J., and De Clercq E. Bioorg. Med. Chem. Lett. 11 (2001) 2137
28. Zoidis G., Kolocouris N., Foscolos G.B., Kolocouris A., Fytas G., Karayannis P., Padalko E., Neyts J., and De Clercq E. Antiviral Chem. Chemother. 14 (2003) 153
29. Stamatiou G., Foscolos G.B., Fytas G., Kolocouris A., Kolocouris N., Pannecouque C., Witvrouw M., Padalko E., Neyts J., and De Clercq E. Bioorg. Med. Chem. 11 (2003) 5485
30. Stylianakis I., Kolocouris A., Kolocouris N., Fytas G., Foscolos G.B., Padalko E., Neyts J., and De Clercq E. Bioorg. Med. Chem. Lett. 13 (2003) 1699
31. Kolocouris A., Spearpoint P., Martin S.R., Hay A.J., López-Querol M., Sureda F.X., Padalko E., Neyts J., and De Clercq E. Bioorg. Med. Chem. Lett. 18 (2008) 6156
32. Kolocouris A., Hansen R., and Broadhurst R.W. J. Med. Chem. 47 (2004) 4975
33. Broadhurst R.W., Kolocouris A., and Zikos C. Bioorg. Med. Chem. Lett. 17 (2007) 3947
34. Czabotar P.E., Martin S.R., and Hay A.J. Virus Res. 99 (2004) 57
35. In the solution NMR structure of a M2 (18-60)-rimantadine complex the drug, in a 200-fold excess, is located on the C-terminus side at helical interfaces, Schnell, J. R.; Chou, J. J. Nature 2008, 451, 591. This structure seems to represent a non-specific drug binding site model according to the recent ssNMR data, see Ref. 6b.
36. The synthesis of most of the ligands (compounds 6, 8, 9, 13-15, 18) has been published; experimental details for compounds 10-12, 16, 17 will be published in the future.
37. See for example:. Krumbholz A., Schmidtke M., Bergmann S., Motzke S., Bauer K., Stech J., Dürrwald R., Wutzler P., and Zell R. J. Gen. Virol. 9 (2009) 900
38. Tang J.W., Ngai K.L., Wong J.C., Lam W.Y., and Chan P.K. J. Med. Virol. 80 (2008) 895
39. Kolocouris, A.; Zell, R. Unpublished data.
40. Astrahan P., Kass I., Cooper M.A., and Arkin I. Proteins 55 (2004) 251
41. See for example:. Warren G.L., Andrews C.W., Capelli A.M., Clarke B., LaLonde J., Lambert M.H., Lindvall M., Nevins N., Semus S.F., Senger S., Tedesco G., Wall I.D., Woolven J.M., Peishoff C.E., and Head M.S. J. Med. Chem. 49 (2006) 5912
42. Leach A.R., Shoichet B.K., and Peishoff C.E. J. Med. Chem. 49 (2006) 5851
43. Cheng T., Li X., Liu Z., and Wang R. J. Chem. Inf. Model. 49 (2009) 1079
44. In contrast recent modelling studies locate no hydrogen bonding for the complex:. Du Q.-S., Huang R.B., Wang C.-H., Li X.-M., and Chou K.-C. J. Theor. Biol. 259 (2009) 159
45. Gandhi C.S., Shuck K., Lear J.D., Dieckmann G.R., DeGrado W.F., Lamb R.A., and Pinto L.H. J. Biol. Chem. 274 (1999) 5474
46. Zürcher M., and Diederich F. J. Org. Chem. 73 (2008) 4345
47. The docking calculations performed on the wild type M2TM sequence of Udorn strain (SSDPLVVAASIIGILHLIL WILDRL) gave similar results; the extra methyl group in residue Ala34 of the mutant sequence (which used for the X-ray structure) seems to assist a little bit aminoadamantane drugs to adopt more stable poses with adamantane orienting towards the wider C-end and ammonium group pointing towards the N-end.